Screener
4D Molecular Therapeutics FDMT Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by 4D Molecular Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:13 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211939
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Loss from operations | (73,620) | (53,621) |
| Other income (expense): | ||
| Interest income | 4,864 | 5,582 |
| Other income (expense), net | (4) | 67 |
| Total other income, net | 4,860 | 5,649 |
| Net loss | $(68,760) | $(47,972) |
| Net loss per share, basic and diluted | $(1.01) | $(0.86) |
| Weighted-average shares outstanding used in computing net loss per share, basic and diluted | 68,064,586 | 55,744,047 |
Item 1. Condensed Financial Statements (Unaudited)
FAQ
- What is 4D Molecular Therapeutics's net income?
- 4D Molecular Therapeutics (FDMT) reported net income of -$68.76M in Q1 2026.
- How has 4D Molecular Therapeutics's net income changed year-over-year?
- 4D Molecular Therapeutics's net income decreased by 43.3% year-over-year, from -$47.97M to -$68.76M.
- What is the long-term trend for 4D Molecular Therapeutics's net income?
- Over 3 years (2021 to 2024), 4D Molecular Therapeutics's net income has grown at a 31.1% compound annual growth rate (CAGR), from -$71.32M to -$160.87M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about 4D Molecular Therapeutics's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude